ReviewNeurodegenerative disease management2016
Managing cognition in progressive supranuclear palsy.
Review in Neurodegenerative disease management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Enteral Nutrition in Idiopathic Parkinson's Disease and Atypical Parkinsonism: A Systematic Review.Movement disorders clinical practice · 2026Pooled it
- Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Clinical patterns in social cognition & personality changes in progressive supranuclear palsy.Journal of neurology · 2026Article
- Cholinergic substrates of gait and postural impairments in Progressive Supranuclear Palsy.Research square · 2026Article
- Article
- Annual percentage change of MR Parkinsonism index in progressive supranuclear palsy: a feasibility study.European radiology · 2025Article
- Article
- Domain-specific brain regions are associated with cognitive impairment in progressive supranuclear palsy.Neuroimage. Reports · 2025Article
- The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research.Diseases (Basel, Switzerland) · 2025Review
- Cognitive impairment in PSP compared with PD: assessment by clinical subtype and longitudinal change.BMJ neurology open · 2025Article
- Biomarker discovery in progressive supranuclear palsy from human cerebrospinal fluid.Clinical proteomics · 2024Article
- Impulse Control Disorders in Parkinson's Disease and Atypical Parkinsonian Syndromes-Is There a Difference?Brain sciences · 2024Article
- Measuring social cognition in frontotemporal lobar degeneration: a clinical approach.Journal of neurology · 2022Review
- Social cognition in the FTLD spectrum: evidence from MRI.Journal of neurology · 2022Review
- Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.Nature reviews. Neurology · 2021Review
- Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.Journal of neurology · 2021Article
- Understanding fatigue in progressive supranuclear palsy.Scientific reports · 2021Article
- Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.Brain communications · 2021Article
- Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.Frontiers in neurology · 2021Review
- Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.Frontiers in neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Cognitive impairment is integral to the syndrome of progressive supranuclear palsy. It is most commonly described as a frontal dysexecutive syndrome but other impairments include apathy, impulsivity, visuospatial and memory functions. Cognitive dysfunction may be exacerbated by mood disturbance, medication and communication problems. In this review we advocate an individualized approach to managing cognitive impairment in progressive supranuclear palsy with the education of caregivers as a central component. Specific cognitive and behavioral treatments are complemented by treatment of mood disturbances, rationalizing medications and a patient-centered approach to communication. This aims to improve patients' quality of life, reduce carer burden and assist people with progressive supranuclear palsy in decisions about their life and health, including discussions of feeding and end-of-life issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.